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SObjective: The ipsilateral hemithorax is the most common site of recurrence after surgical resection for malig-
nant pleural mesothelioma. Salvage treatment has generally been ineffective. We reviewed the outcomes after
resection of isolated ipsilateral chest recurrence after cytoreductive surgery in patients with malignant pleural
mesothelioma.
Methods: Patients with malignant pleural mesothelioma who underwent initial surgical resection at our insti-
tution from 1988 to 2011 and were subsequently treated for localized recurrence with an additional chest resec-
tion were identified and their data retrospectively reviewed.
Results: A total of 1142 patients underwent either extrapleural pneumonectomy (n ¼ 794) or pleurectomy/
decortication (n ¼ 348). Of the patients who returned for follow-up, 47 (4.1%) had chest wall recurrence
amenable to resection. The location of recurrence was predominantly incisional (49%) and/or costophrenic
(38%). The median time to recurrence after either extrapleural pneumonectomy or pleurectomy/
decortication was 16.1 months (range, 2.7-58.2). No 30-day mortality was found for chest wall resection, and
the median length of stay in the hospital was 3 days (range, 0-12). The median overall survival duration after
chest wall resection correlated positively with the time to recurrence (epithelial: median, 8.9, 17.2, and 35.8
months for a time to recurrence of<12, 12 to<24, and 24 months, respectively; biphasic: median, 2.7 and
15.9 months for a time to recurrence of<10 and 10 months, respectively).
Conclusions: Chest wall resection is a safe and effective therapeutic option in the management of localized
chest wall recurrence of malignant pleural mesothelioma. The time to recurrence appears to be predictive of
the expected survival benefit in both epithelial and biphasic malignant pleural mesothelioma. (J Thorac Cardi-
ovasc Surg 2013;146:1373-80)Malignant pleural mesothelioma (MPM) is an aggressive
malignancy with a poor prognosis and few effective
treatment options. Without treatment, the median survival
has been 6 to 9 months. Single modality therapy has
provided a marginal survival benefit.1,2 Combination
chemotherapy (pemetrexed with cisplatin vs cisplatin
alone) has been shown to be superior to single agent
chemotherapy.3 Surgery-basedmultimodality therapy, how-
ever, has become the mainstay of treatment of resectable
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The Journal of Thoracic and Carbeen reported from various centers.4 Despite the progress
seen with multimodality therapy, the high rate of recurrence
after the initial resection has correlated with reduced
survival. In a study investigating patterns of failure after
trimodality therapy, the most common site of recurrence
(35% overall and 67% of all recurrences) was the ipsilateral
hemithorax.5,6 However, no effective strategies have been
described in the published data regarding the treatment of
isolated ipsilateral chest recurrence. Although systemic
chemotherapy and radiotherapy remain the most common
treatment approaches for recurrent disease, neither has
offered a significant survival benefit.7,8 The role of
surgical resection of ipsilateral chest wall recurrences has
not been established in published studies.
The aim of the present study was to evaluate the
morbidity, mortality, and survival rates associated with
surgical resection of isolated ipsilateral chest wall
recurrences after cytoreductive surgery for MPM.
METHODS
Patients
With approval from the institutional review board, we retrospectively
reviewed the records of all patients in the International Mesothelioma Pro-
gram Patient Data Registry at Brigham andWomen’s Hospital who had un-
dergone cytoreductive surgery by either extrapleural pneumonectomy
(EPP) or pleurectomy/decortication (PD) from January 1, 1988, throughdiovascular Surgery c Volume 146, Number 6 1373
FIGURE 1. Location of isolated ipsilateral chest wall recurrence of
malignant pleural mesothelioma after cytoreductive surgery.
Abbreviations and Acronyms
CT ¼ computed tomography
CWR ¼ chest wall resection
EPP ¼ extrapleural pneumonectomy
MPM ¼ malignant pleural mesothelioma
PD ¼ pleurectomy/decortication
TTR ¼ time to recurrence
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SJanuary 31, 2011. We identified all patients who had subsequently under-
gone chest wall resection (CWR) for a solitary recurrence that was isolated
to the ispilateral chest wall. We considered CWR to entail resection of at
least 1 rib and potentially included adjacent structures such as muscle
and soft tissue, costal cartilages, the sternum, or diaphragm. The electronic
and written medical records of these patients were reviewed to obtain
clinicopathologic data. Survival was confirmed from the medical records,
obituaries, and/or the Social Security Death Index. Our standard post-
operative surveillance practice has been to monitor these patients with
serial chest computed tomography (CT) scans, supplemented by positron
emission tomography-CT for suspicious findings. A postoperative chest
CT scan was arranged approximately 2 months after EPP or PD to
establish a new baseline and rule out residual disease. The CT scans
were then scheduled every 4 months for the next 2 years, after which the
surveillance interval was increased. The time to recurrence (TTR) was
defined as the interval after EPP or PD to the diagnosis of recurrence.
The sites of recurrent disease were further characterized as (1) incisional
(site of posterolateral thoracotomy), (2) costophrenic (lower chest wall
or diaphragm), (3) paraspinal or sternal, or (4) superior chest (including
the axilla).
Statistical Analysis
Statistical analysis was conducted using JMP statistical software,
version 8.0 (SAS Institute, Cary, NC). For all statistical testing, we used
a 2-sided significance level ofP¼ .05. Descriptive statistics were collected.
Where appropriate, the results are reported as the median and range for
continuous variables. Between-group comparisons were made using the
Mann-Whitney U test for continuous variables and a chi-square test for
categorical variables. Kaplan-Meier plots were used to estimate the
survival functions for overall survival, defined as the point from the primary
resection or first chest wall metastasis resection until death from any cause
after surgery. The TTR was defined as the interval between an EPP or PD
and the first sign of recurrence confirmed by imaging or on clinical
examination. Differences in the survival outcome between patient groups
were compared using the log-rank test.
RESULTS
Of the 1142 patients who underwent cytoreductive
surgery by either EPP (n ¼ 794) or PD (n ¼ 348) during
the study period, 47 (4.1%) were identified who had
subsequently developed ipsilateral local chest wall
recurrence and underwent surgical resection. In these 47
patients, the recurrence was diagnosed by chest CT in 17,
positron emission tomography-CT in 16, biopsy in 10,
palpation in 3, and magnetic resonance imaging in 1. Of
the 47 patients, 16 (34%) underwent repeat CWR for a
second recurrence, and 3 underwent a third CWR for
solitary recurrent disease. Thirteen of these 16 patients
were in the epithelial group (n ¼ 32). The median age1374 The Journal of Thoracic and Cardiovascular Surwas 61.9 years (range, 27.3-82.0). Most of the patients
(77%) were men. The presenting symptoms included a
palpable mass in 77% and chest wall pain in 36%. Most pa-
tients (68%) had epithelial histology found by pathologic
analysis of the primary resection specimen. The remaining
32% of patients had biphasic histology; no cases were
found of sarcomatoid type MPM in our study. Ten patients
(21%) had N2 disease. Of the 47 patients, 32 (68%) had
initially been treated with EPP and 15 by PD (32%).
Also, 28% of the patients required mesh reconstruction of
the chest wall defect after CWR, 63% were closed prima-
rily, and 9% underwent muscle flap closure. The 30-day
mortality was 0%, and no complications such as wound
infection, bleeding, or dehiscence were seen. The median
length of stay in the hospital was 3 days (range, 0-12).
The distribution of chest wall recurrence resection sites is
depicted in Figure 1. Of the recurrences, 49% were in the
original thoracotomy incision, 38% were in the costo-
phrenic region, and 9% were in the axilla or upper chest.
One patient underwent a paraspinal resection, and one
underwent sternal resection for recurrent disease. Resection
in 2 patients included partial hepatectomy for en bloc
removal of contiguous tumor as a part of the CWR (costo-
phrenic region); 2 other patients underwent resection of dis-
ease at the ipsilateral diaphragmatic crura and mediastinum
for contiguous disease at the costophrenic recurrence resec-
tion. Of the 16 patients who underwent a second CWR for a
second chest wall recurrence, the recurrence site was at the
previous site of CWR in 9 patients (56%) and was at a new
site on the chest wall in 7 (44%). Among those patientsgery c December 2013
FIGURE 2. Interval to isolated, ipsilateral chest wall recurrence of malig-
nant pleural mesothelioma after cytoreductive surgery. RFS, Recurrence-
free survival.
FIGURE 3. Overall survival after chest wall resection (CWR) for isolated,
ipsilateral chest wall recurrence of malignant pleural mesothelioma after
cytoreductive surgery. MS, Median survival.
Burt et al General Thoracic Surgery
G
T
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the disease recurred at the site of the CWR in 1 and was
at a new site on the chest wall in 2. Of the 15 patients
with biphasic cell type at EPP or PD, 10 were found to
have either epithelial (n ¼ 8) or sarcomatoid (n ¼ 2) histo-
logic features at their CWR. In contrast, all 32 patients with
epithelial histologic features on the initial EPP or PD re-
tained an epithelial histologic type on chest wall recurrence.
As shown in Figure 2, the median TTR for the present
cohort was 16.1 months (range, 2.7-58.2). For those with
the epithelial type, it was 23.4 months (range, 2.7-58.2),
significantly longer (P ¼ .022) than the TTR for those
with the biphasic type at 11.2 months (range, 2.7-43.4).
The median interval to CWR from primary EPP or PD was
22.4 months (range, 2.7-105.7). For patients with epithelial
histologic features, it was 29months (range, 2.7-105.7), and
for those with biphasic histologic features, it was 11.7
months (range, 4.6-45.5). The overall median survival
from the initial cytoreductive surgery for all patients
undergoing CWR was 44.9 months (range, 3.8-130.5).
As shown in Figure 3, the survival from CWR was
significantly longer (P¼ .01) among patients with epithelial
histologic features (median, 20.4 months; range, 1-73.1)
than for those with mixed histology (median, 7.4 months;
range, 1.3-34.7). Patients with epithelial type tumors were
categorized into 3 subgroups according to the TTR: less
than 12 months, 12 to less than 24 months, and 24 months
or longer. Patients with biphasic type tumors were catego-
rized into 2 subgroups (TTR < 10 and TTR of  10
months). The basis for these categorizations was the num-
ber of patients and the range of TTR in each group. Overall
survival after CWR was positively related to the TTR forThe Journal of Thoracic and Carboth epithelial (Figure 4, A) and biphasic (Figure 4, B)
cell types. For those with the epithelial type, the median
survival after CWR was 35.8 months when the TTR was
24 months or longer, 17.2 months when it was 12 to less
than 24 months, and 8.9 months when it was less than 12
months (P ¼ .001). For those with the biphasic type, the
median survival after CWR was 15.9 months when the
TTR was 10 months or longer and was only 2.7 months
when the TTR was less than 10 months (P ¼ .002). Early
recurrence (within 6 months) was seen in 4 patients with
epithelial and 2 patients with biphasic MPM.
With the exception of age for the epithelial cell type,
none of the patient characteristics, tumor characteristics,
or treatment parameters were significantly different
among the patient subgroups for either epithelial or biphasic
histologic types (Tables 1 and 2). For the epithelial type, the
median age of the subgroups with a TTR of less than
12 months, 12 to less than 24 months, and 24 months
or longer was 73, 62, and 51 years, respectively. The
difference was statistically significant (P ¼ .03).
At their original EPP or PD, 3 patients were treated with
neoadjuvant chemotherapy and 17 patients (36%) received
adjuvant chemotherapy. Also, 24 patients (51%) were
treated with heated intraoperative chemotherapy, and 20
(43%) received adjuvant radiotherapy. At the diagnosis of
recurrent disease, 23 patients (49%) were treated with
chemotherapy and 10 (21%) with radiotherapy.DISCUSSION
Recurrent disease in the ipsilateral chest is themost common
site of first failure after surgery-basedmultimodality treatment
of MPM.5 Early in the disease course, MPM tends to spread
along the ipsilateral pleura. Metastatic dissemination to sites
other than the abdomen or contralateral lung is uncommon
but can occur in later phases of the disease or in patients who
survive a long time after aggressive local therapy. With no
treatment, most patients experience progressive local diseasediovascular Surgery c Volume 146, Number 6 1375
FIGURE 4. Overall survival after chest wall resection (CWR) for an
isolated, ipsilateral chest wall recurrence stratified by the time to
recurrence (TTR) for A, epithelial and B, biphasic histologic tumors.
MS, Median survival.
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complications arising from this process.2
Very little has been described in published studies with
respect to salvage chest surgery for recurrent MPM. The
only other study of this type was by Politi and Borzellino.9
They reported 4 patients who had undergone CWR, 3 with
retroperitoneal resection, and 1 with segmental lung
resection.9 Although these investigators did not report
extended survival after resection, the small sample size
rendered any meaningful interpretation difficult.
The biology of epithelial and nonepithelial MPM tumors
is different enough that we believe these tumors should be
considered separately in any clinical or biologic analyses.
The tumor histologic type is a well-established predictor
of survival.10 This finding was also demonstrated in our
study, in which the epithelial cell type was associated with
greater overall survival. Furthermore, among patients with
epithelial histologic features, younger age was associated1376 The Journal of Thoracic and Cardiovascular Surwith a longer interval to recurrence. This finding was also
consistent with our earlier reported series on long-term
survivors of MPM.11 From these results, the histologic
type and patient age should be considered when evaluating
the potential benefit of repeat resection in the setting of
isolated metastasis.
We found that survival after repeat resection increases in
an orderly manner with increasing TTR. This finding could
help inform discussions of the risk/benefit ratios for second
resection for patients diagnosed with an isolated recurrence.
The histologic features of the original resection will provide
additional refinement of the prognosis. For epithelial MPM,
patients with a TTR in excess of 24 months had a median
survival of an additional 35.8 months after CWR. In
contrast, for patients with biphasic MPM, which tended to
recur early in the postoperative period after primary EPP
or PD, only an additional 2.7 months survival was achieved
after CWR if the TTR was less than 10 months. Thus, this
latter group of patients might be better served by palliation
or salvage modalities such as chemotherapy or radio-
therapy, or both.7,8 For example, on occasion, we will use
stereotactic ablative radiotherapy to chest wall metastases
in patients who are not candidates for CWR, with good
anecdotal results.
At EPP or PD, the tumor cells can also disseminate into
the operative field or contaminate the incision. In many
cases, it is plausible that this was the etiology of recurrent
disease. We found that the most common site of ipsilateral
chest wall recurrence was along the original thoracotomy
incision (49%), followed by the costophrenic sulcus
(38%, Figure 1). Recurrence along the thoracotomy inci-
sion most likely results from tumor seeding, and 1 potential
method for addressing this is by modifications in the surgi-
cal technique. Our practice has included minimizing dissec-
tion planes at the thoracotomy incision site (ie, minimize
the blunt dissection often performed to identify the correct
rib space), performing a chemical wash of the thoracotomy
incision with hydrogen peroxide, and performing a distilled
water and saline lavage with a pulsed lavage irrigator.
Radiotherapy has also been used as a prophylactic treatment
to reduce the incidence of recurrence in incisional sites;
however, the reported efficacy for this has been mixed.12-14
It is often difficult to obtain complete surgical clearance of
tumor in the costophrenic sulcus, and, as such, it is not
surprising that this location is another common site of
relapse. Furthermore, for patients who undergo radiotherapy
as a part of their trimodal therapy, this has been a common
site of local recurrence.15-17 Two explanations for
costophrenic recurrence after radiotherapy include that,
first, the treatment field borders sometimes do not extend
as inferiorly as they should (at least to the bottom of L2),
and, second, for technical reasons, the costophrenic sulcus
is a common area of dose inhomogeneity. Moreover, it is
difficult to escalate the radiation dose to the costophrenicgery c December 2013
TABLE 1. Demographics and clinical and pathologic characteristics of patients with epithelial cell type undergoing chest wall resection for local
mesothelioma recurrence (n ¼ 32)
Variable
All epithelial
cell type patients
Epithelial  12-mo
TTR (group 1)
Epithelial 12-24 mo
TTR (group 2)
Epithelial  24-mo
TTR (group 3) P value
Patients (n) 32 7 (21.9) 10 (31.3) 15 (46.9)
Median age (y) 64 73 62 51 .03
Gender .7
Female 10 (31) 3 (42.8) 3 (30) 4 (26.7)
Male 22 (69) 4 (57.14) 7 (70) 11 (73.3)
Laterality .2
Right 19 (59) 3 (42.9) 8 (80) 8 (53.3)
Left 13 (41) 4 (57.1) 2 (10) 7 (46.7)
Pain* .3
No 21 (66) 3 (42.9) 8 (80) 10 (66.7)
Yes 11 (34) 4 (57.1) 2 (20) 5 (33.3)
Palpable mass* .2
No 8 (25) 0 4 (40) 4 (26.7)
Yes 24 (75) 7 (100) 6 (60) 11 (73.3)
Initial surgical approach .5
PD 12 (37) 3 (42.9) 5 (50) 4 (26.7)
EPP 20 (63) 4 (57.1) 5 (50) 11 (73.3)
N2 disease .3
No 24 (75) 4 (57.1) 7 (70) 13 (86.7)
Yes 8 (25) 3 (42.9) 3 (30) 2 (13.3)
Reconstruction with mesh* .06
No 23 (72) 7 (100) 8 (80) 8 (53.3)
Yes 9 (28) 0 2 (20) 7 (46.7)
Second CWR 1.0
No 19 (59) 4 (57.1) 6 (60) 9 (60)
Yes 13 (41) 3 (42.9) 4 (40) 6 (40)
Data presented as n (%), unless otherwise noted. TTR,Time to recurrence; PD, pleurectomy/decortication; EPP, extrapleural pneumonectomy;CWR, chest wall resection. *At the
time of CWR.
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kidneys and liver (for right-sided cases) and stomach (for
left-sided cases). Of the 47 patients in our cohort, 18
(38%) underwentCWRfor a costophrenic angle recurrence.
Of these 18 patients, 7 (39%) received postoperative radio-
therapy. Finally, the lower chest wall is a common site to
enter the chest when obtaining a pleural biopsy to establish
a diagnosis. Tumor dissemination occurs in up to 40% of
thoracoscopy sites and up to 10.4% of needle biopsy
tracts.12-14,18 We have, therefore, implemented a standard
practice of excising all thoracoscopy and needle biopsy
sites, when feasible, at EPP and PD.
Of the recurrences in the present series, 87% were in the
lower chest (costophrenic and incisional combined) and
only 9% were in the apex or axilla (Figure 1). This pattern
of recurrence is consistent with the natural history of MPM
and its distribution in the pleural space, such as can be seen
in patients at their EPP or PD. Among the patients in the
present cohort who underwent resection for a costophrenic
recurrence, some had disease in the lower chest wall that
had directly invaded the retroperitoneum and/or abdomen.
Two patients in this group underwent partial hepatectomy
for contiguous disease, and another two had contiguousThe Journal of Thoracic and Caripsilateral diaphragmatic crural and/or mediastinal involve-
ment, which was also resected at their CWR. When
resecting recurrences in patients with contiguous disease,
our goal has been to remove all involved structures en
bloc in an attempt to perform a proper oncologic resection.
For the patients who underwent a second CWR for
isolated recurrence, a longer overall median survival was
noted. Multiple serial resections for locally recurrent
MPM can be associated with prolonged survival, similar
to that seen after repeated metastasectomies performed for
pulmonary metastases in other diseases.2,19,20
Performing a second surgery on patients with MPM
allowed us to compare the histologic cell type at the first
surgery with that at the CWR (second surgery). We noted
an interesting trend in that more than one half of the patients
diagnosed with a biphasic cell type at the initial surgery
were found to have a predominantly epithelial cell type
(53%) at their second surgery. This might have resulted
from the selection of the epithelial component as retained
viable microscopic disease after surgery and/or adjuvant
modalities such chemoradiotherapy. Alternatively, biphasic
MPM might transition to predominantly the epithelial or
sarcomatoid type in certain cases of recurrent disease,diovascular Surgery c Volume 146, Number 6 1377
TABLE 2. Demographics and clinical and pathologic characteristics
of patients with biphasic cell type undergoing chest wall resection for
local mesothelioma recurrence (n ¼ 15)
Variable
All biphasic
cell type
patients
Biphasic
cell type,
0-10 mo
TTR (group 1)
Biphasic
cell type
>10 mo
TTR (group 2)
P
value
Patients 15 5 (33.3) 10 (66.6)
Median age (y) 62 58 64 .59
Gender .1
Female 1 (7) 1 (20) 0
Male 14 (93) 4 (80) 10 (100)
Laterality .7
Right 11 (73) 4 (80) 7 (70)
Left 4 (41) 1 (20) 3 (30)
Pain* .3
No 9 (60) 4 (80) 5 (50)
Yes 6 (40) 1 (20) 5 (50)
Palpable mass* .3
No 3 (20) 0 3 (30)
Yes 12 (80) 5 (100) 7 (70)
Surgical approach 1.0
PD 3 (20) 1 (20) 2 (20)
EPP 12 (80) 4 (80) 8 (80)
N2 disease .3
No 13 (87) 5 (100) 8 (80)
Yes 2 (13) 0 2 (20)
Reconstruction
with mesh*
.7
No 11 (73) 4 (80) 7 (70)
Yes 4 (27) 1 (20) 3 (30)
Second CWR 1.0
No 12 (80) 4 (80) 8 (80)
Yes 3 (20) 1 (20) 2 (20)
Data presented as n (%), unless otherwise noted. TTR, Time to recurrence;
PD, pleurectomy/decortication; EPP, extrapleural pneumonectomy; CWR, chest
wall resection. *At the time of CWR.
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with transition to an epithelial type are more likely to
present with an isolated recurrence and thosewith transition
to a sarcomatoid type are more likely to develop multiple
recurrences. Additional studies are needed to investigate
this phenomenon.
The main limitations of our study were its retrospective
nature and the highly selected patient cohort. We only
reviewed patients who returned for follow-up to our clinic
and underwent CWR for localized and solitary recurrence.
The follow-up of all 1142 patients undergoing EPP or PD
was not sufficient to provide an accurate depiction of the
incidence of chest wall recurrence that is amenable to
CWR. Thus, the true percentage of patients who might
have developed diffuse and multiple chest wall metastases
could not be accurately derived. Another potential draw-
back of our study was that a large number of patients
received adjuvant therapy, and some were treated with
chemotherapy and/or radiotherapy for recurrent disease1378 The Journal of Thoracic and Cardiovascular Surbefore repeat resection. This wide variety of adjunct thera-
peutic modalities likely represents the evolution of our
approach to patients with MPM, and the evolution of our
investigational protocols during the 23-year study period. It
would be difficult to ascertain the role these treatments might
have played in addition to the CWR in extending patient sur-
vival after CWR. For reference, our current treatment
approach includes preoperative cervical mediastinoscopy
for all patients with MPM, and patients with pathologically
determined N2 disease are recommended to undergo neoad-
juvant chemotherapy. At our institution, patients undergoing
EPP or PD are usually offered heated intraoperative chemo-
therapy. Despite these limitations, we believe our study had
a number of strengths, including a relatively large sample
size with localized chest wall recurrence and treatment at an
institution highly experienced in treating patients withMPM.
In conclusion, our results have indicated that for select
patients with isolated chest wall recurrence of MPM,
salvage CWR (performed with an intent to cure) is an
effective strategy associated with favorable survival rates
at the expense of minimal morbidity. Patients with a
prolonged TTR will benefit the most. It is appropriate to
consider curative CWR as standalone therapy or in conjunc-
tion with other adjuvant modalities in the management of
localized ipsilateral chest recurrence for patients with a
good performance status and for whom the anticipated
surgical morbidity is minimal.References
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Discussion
Dr Walter Weder (Zurich, Switzerland). I would like to
congratulate Dr Ali and the group from Boston for their clinically
relevant contribution to surgical treatment of local recurrences by
chest wall resection in patients with malignant pleural mesotheli-
oma. I received the report in time for a critical review.
Dr Ali and colleagues identified 47 patients with local recur-
rence of malignant pleural mesothelioma who were amenable
for resection of 1142 patients who had undergone radical resection
either by EPP (794 patients) or PD (348 patients). This accounts
for 4.1% of all operated cases. Taking into consideration that the
reported local recurrence rate in the ipsilateral chest after EPP is
around 35% to 40% and probably even higher after PD, only
around 12% of all patients with local recurrence were selected
for surgical treatment. In part, this relatively small number
was because patient follow-up was done outside your service.
Nevertheless, it seems that you have been very selective.
This brings me to my first question. How did you exactly select
your patients? Was it based primarily on CT scan, looking for a
localized resectable bulk, or was the clinical picture more
important—nonfixed tumor, pain? Is there an upper tumor size
or tumor extension? How important are the positron emission
tomography findings, which clearly show local extension more
precisely? Does it matter if the planned resection will be radical
or not? Is patient selection for chest wall resection different for
patients after EPP than after PD?
Dr Ali. The way we select our patients is we follow them up in
our postoperative clinic and we obtain routine CT scans. The first
CT scan is done at 6 to 8 weeks and serves as a baseline. There-
after, we repeat the CT scans every 4 months. Usually on imaging
or on the clinical examination, if there is a suspicion of recurrent
disease, we often obtain a positron emission tomography-CT
scan. This is how we identify recurrent disease.
As far as who is a good candidate for chest wall resection, this is
basically solitary or isolated disease. As we saw in this breakdown,The Journal of Thoracic and Carabout one half of them were at the incisional site, and 38% were at
the costophrenic angle. As you can imagine, the incisional site is
most likely because of tumor seeding, and perhaps the disease at
the costophrenic angle was secondary to this being a difficult
area to achieve macroscopic clearance at. The patients are selected
primarily on the criteria based on the question, ‘‘Can we achieve
complete resection and return them to their decreased tumor
burden?’’ It is like resetting the tumor burden. If we believe the
patient has more than 1 thoracic recurrence (ie, it is not solitary
disease), we would offer them surgery. However, this study
included only patients with solitary recurrent disease. If
extrathoracic diseases present, as well as chest wall recurrence,
generally speaking, they would not be offered chest wall resection.
As to your last point, the extent of resection, for patients
who had disease in the costophrenic sulcus, often it extends
contiguously into the retroperitoneum, and we had at least
3 patients in this study who ended up undergoing an en bloc
retroperitoneal mass resection. In 2 patients, the disease extended
toward the mediastinum, and the remnant diaphragmatic crura was
resected en bloc with the chest wall resection.
Dr Weder. In your study, you showed nicely that early recur-
rence is a poor prognostic sign, an observation also made in other
clinical questions with malignancies, such as surgical treatment of
metastasis. My second question regards the indication for surgery
in relation to the onset of the recurrence. In which cases do you not
recommend surgery because of the expected aggressive biologic
behavior of the tumor? Is there a recommended cutoff time?
Dr Ali. That is a very good question. As you know, in
mesothelioma, the primary determinant of survival is the cell
type, or, in other words, the tumor biology. The epithelial cell
type tends to have a longer survival. In this study, patients who
had their first recurrence after primary macroscopic resection,
when the TTR (or time to recurrence) was more than 24 months,
their median survival was 35.9 months. Now, in the same study,
we had patients with biphasic-type disease whose TTR was less
than 10 months, and their median survival after chest wall
resection was a mere 2.7 months. So clearly, the tumor biology
is an important determinant. I think this allows us to determine
the criteria according to the TTR as to which patients we should
offer a second surgery to.
Dr Shrager. I think his question was what criteria would you
propose.
Dr Ali. I think for the biphasic type, when they recur early,
you have to consider other therapies, such as radiotherapy or
second-line, third-line chemotherapy, especially when they recur
within less than 10 months. Now, this study has 47 patients who
were highly selected. So I think we can use this as a guideline in
the future, especially for the biphasic type.
Dr Weder. But those with the epithelial type, those with early
recurrence had a very poor prognosis. So, I would not make the
cutoff exactly just for the mixed type. I think also the epithelial
type can behave very aggressively when it occurs early. So my
last question is, what about local recurrence after chest wall
resection, especially in these aggressive subtypes, did you see
problems in this regard?
Dr Ali. Yes. One third of these patients ended up undergoing a
second chest wall resection. We believe if there is repeat
recurrence and if we can resect it and return the patients back todiovascular Surgery c Volume 146, Number 6 1379
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Stheir previous tumor burden, that is, reset their homeostasis, so to
speak, then we would offer them surgery. The median survival for
patients who had undergone 2 or more resections was actually 59
months. So, in a way, in this highly selected subset of patients,
repeat recurrence was not an impediment to repeat resection.
Dr Weder. Also, for the one who had occurred early, the very
aggressive one, you have not seen recurrence there?
Dr Ali. No. Those who recurred early, no, we did not.
Dr Weder. Thank you very much.
Dr Robert B. Cameron (Los Angeles, Calif). I want to
congratulate you on an obviously impressive series. I have a lot
of questions, but I will limit them to 2.
First is regarding the 25-year period that you are reporting on.
I am just curious, because a number of other things have
been developed during that 25 years, including stereotactic
body radiotherapy, radiofrequency ablation, and other localized
treatments that are short of surgery. Can you comment on the
use of those in your series? Did you use any of them, and did
you find that they were less effective? Also, in light of that, does
any difference exist in morbidity in performing chest wall
resection vs performing stereotactic body radiotherapy?
Dr Ali. That is a very good question. These are cases from our
database, and the selection criterion was to include patients who
had undergone chest wall resection for solitary disease. So in this
study, we could not compare other modalities based on that. Having
said that, for recurrent disease at the costophrenic sulcus, for
example, radiotherapy often has its limits of how much radiation
you can give. There are radiosensitive organs at the costophrenic
sulcus such as the stomach on the left and liver on the right, and, sec-
ond, often patients have reached theirmaximum radiation limit after
multimodality therapy for mesothelioma. In patients who have un-
dergone PDwith their lung still in the ipsilateral chest, radiotherapy
can be associated with side effects such as radiation pneumonitis.
So, clearly, there are certain side limitations one must keep in
mind. I cannot comment on which technique is superior.1380 The Journal of Thoracic and Cardiovascular SurDr Cameron. I would like to take the opportunity, then, to
invite you to the ethereal world of the ‘‘POD.’’We have an abstract
that is in the POD downstairs, wherever that is, that reports on 86
lesions that were treated with cryoablation of local recurrence after
pleurectomy, and we had a success rate of permanent control of
those lesions 98% of the time without any surgery. So, I would
just invite you to review that because I think that that will basically
obviate the need for any chest wall resection, and a lot of those
were chest wall recurrences that were treated successfully up to
6 cm.
I have to ask 1 last question, which is kind of the elephant in the
room. Whenever you talk about mesothelioma, everybody says,
well, we have no randomized trials and all that sort of thing, but
you just reported on almost 800 EPPs.With the mounting evidence
from a number of different groups, including the Mesothelioma
and Radical Surgery (MARS) trial, that EPP might not have any
benefit in this disease, are we going to be hearing in the near future
about your randomized prospective clinical trial of EPP and
whether it works or not?
Dr Ali. I think in surgery for mesothelioma, there could be
some debate, but clearly the results from our institution show
that excellent survival can achieved using a multimodality,
surgery-based approach, and I think what we are showing here
today is that a second surgery for select cases should also be
considered.
Dr Antoon Lerut (Leuven, Belgium). Thank you for an
excellent presentation.
I would like to come back to the 1 of 3 patients who underwent a
second chest wall resection. You mentioned that the overall
median survival was 59 months from the date of primary surgery,
but what was the median survival from the date of the second
chest wall resection? That perhaps might give an idea about the
aggressiveness of the second recurrence.
Dr Ali. In those 16 patients, their median survival after the
second resection was 14.5 months.gery c December 2013
